NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

NexImmune, Inc., Yale, and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.